Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Relacorilant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Corcept Submitted Lead Asset For Approval Despite FDA Warning
    Corcept Submitted Lead Asset For Approval Despite FDA Warning

    30 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/corcept-submitted-lead-asset-approval-despite-fda-warning-success-was-unlikely

    FIERCE BIOTECH
    30 Jan 2026
    Share Share
    Corcept's Cancer Drug Cuts Risk Of Death In Ovarian Cancer Trial
    Corcept's Cancer Drug Cuts Risk Of Death In Ovarian Cancer Trial

    23 Jan 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/corcepts-cancer-drug-meets-main-goal-late-stage-trial-2026-01-22/

    REUTERS
    23 Jan 2026
    Share Share
    Corcept Gets Complete Response Letter For Relacorilant
    Corcept Gets Complete Response Letter For Relacorilant

    31 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251231309474/en/Corcept-Receives-Complete-Response-Letter-for-Relacorilant-as-a-Treatment-for-Patients-with-Hypercortisolism

    BUSINESSWIRE
    31 Dec 2025
    Share Share
    Corcept’s Relacorilant Benefits PARPi-Treated Ovarian Cancer
    Corcept’s Relacorilant Benefits PARPi-Treated Ovarian Cancer

    19 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251019109551/en/Corcept-Presents-ESMO-2025-Late-Breaker-Relacorilant-Demonstrates-Benefit-in-Patients-with-Platinum-Resistant-Ovarian-Cancer-with-Prior-PARP-Inhibitor-Treatment

    BUSINESSWIRE
    19 Oct 2025
    Share Share
    Corcept Seeks EMA Approval For Relacorilant
    Corcept Seeks EMA Approval For Relacorilant

    14 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251014154513/en/Corcept-Submits-Marketing-Authorization-Application-to-European-Medicines-Agency-for-Relacorilant-as-a-Treatment-for-Patients-with-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    14 Oct 2025
    Share Share
    Corcept Shares ROSELLA Trial Data in Ovarian Cancer at ESMO
    Corcept Shares ROSELLA Trial Data in Ovarian Cancer at ESMO

    22 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250922541539/en/Corcept-to-Present-New-Late-Breaking-Data-From-Pivotal-ROSELLA-Trial-of-Relacorilant-in-Platinum-Resistant-Ovarian-Cancer-at-ESMO-2025

    BUSINESSWIRE
    22 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.